title: [Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014].
abstract: OBJECTIVE
  The objective of the study was to describe the trends of utilization, supply and prevalence of hormone replacement therapy (HRT) in Spain during the period 2000-2014.
  
  
  METHODS
  Annual prevalence of HRT use including the 95% CI was calculated for women aged≥40 using individual data from the national population-based database BIFAP. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1,000 inhabitants per day and were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the Spanish National Health System.
  
  
  RESULTS
  In the year 2000, overall HRT consumption was 33.12 DDDs/1000 inhabitans/day: 19.81 for oestrogen only, 6.88 for tibolone and 6.44 for combined oestrogen and progestagen. In 2014 overall HRT consumption was 5.32 DDDs/1000 inhabitans/day: 1.08 for oestrogen only, 1.61 for tibolone and 2.62 for combinations of oestrogen and progestagen. The marketed presentations of HRT decreased by 46.9%. Prevalence of HRT use in women aged≥40 in BIFAP was 7.19% (95% CI 6.97-7.40) in 2001 and 0.21% (95% CI 0.20-0.22) in 2014. Women aged 40-45 registered the highest prevalence of use in 2014: 0.71% (95% CI 0.66-0.76).
  
  
  CONCLUSIONS
  A sharp decline in the consumption and prevalence of HRT has been observed in Spain since the publication of the Women's Health Initiative and Million Women Study and the regulatory measures taken restricting conditions of use, showing a similar trend to that of other western countries.
authors.affiliation: Servicio de Farmacia Hospitalaria, Hospital Universitario La Paz, Madrid, España.
authors.forename: Laura
authors.initials: L
authors.lastname: Baladé Martínez
authors.affiliation: División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España.
authors.forename: Dolores
authors.initials: D
authors.lastname: Montero Corominas
authors.affiliation: División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España. Electronic address: dmacias.sg@gmail.com.
authors.forename: Diego
authors.initials: D
authors.lastname: Macías Saint-Gerons
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends*; D011372:Progestins / Q000627:therapeutic use*; D013030:Spain
chemical_list: D000726:Androgen Antagonists; D004967:Estrogens; D009652:Norpregnenes; D011372:Progestins; C027385:tibolone
keywords: Drug utilization study; Estudio de utilización; Hormone replacement therapy; Menopause; Menopausia; Tratamiento hormonal de sustitución